The FDA proposed that each June the Vaccines and Related Biological Products Advisory Committee (VRBPAC) would meet and determine the composition of a COVID-19 vaccine to used as a booster or primary immunization in the fall. The FDA further proposed use of a bivalent vaccine for both primary and booster immunizations. Patients that have been immunized with a COVID-19 vaccine in the past would receive one vaccination. Patients who have not received a COVID-19 vaccination (i.e. young children) or those with a blunted immune response (i.e. elderly patients or immunocompromised patients) would receive two doses. The VRBPAC agreed and voted 21-0 to recommend a harmonized bivalent composition for COVID-19 for primary and booster vaccines.
Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker